HIV/AIDS Coinfection
HIV coinfection does not alter efficacy of hepatitis C treatment
Published in Hepatitis Weekly, January 19th, 2004
In a recent study, scientists in the United States examined HCV and HIV dynamics "in 10 coinfected subjects in a trial of pegylated interferon- alpha2a (PEG- IFN) alone or combined with ribavirin (RBV), compared with IFN plus RBV for the treatment of HCV."
"Five subjects, four of whom were treated with PEG-IFN, achieved a sustained virological response, although it was delayed by {{>=}}1 week in three subjects," reported F.J. Torriani and coauthors at the University of California-San Diego.
"The median treatment efficacy in blocking...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-01-19)
More Articles from Hepatitis Weekly
- Addiction Medicine
Bilirubin is a simple marker for alcoholic hepatitis treatment response - Diagnostic Evaluation
SPECT asialoglycoprotein receptor dynamics reveal hepatitis status - Gastroenterology
Carbon monoxide combines with nitric oxide to protect liver cells - Hematology
Elevated cobalamin levels may indicate severe liver disease - Hepatitis B Vaccine
Immunity persists 4 years after hepatitis B vaccination - Hepatitis B Virus
Rates on the decline in the United States but not among adults - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
